Surging global demand for GLP-1 receptor agonist medications has created unprecedented logistics bottlenecks within cold-chain supply operations. Pharmaceutical distribution networks are allocating significant capital to double their refrigerated storage capacity over the next two years.
Supply Constraints and Market Scalability
Active Pharmaceutical Ingredient (API) production throughput remains the primary bottleneck for drug developers. To mitigate distribution gaps, contract development and manufacturing organizations are securing multi-year capacity reservation agreements with major pharmaceutical brands.